Sildenafil Treatment for Mild TBI

Status Terminated

Clinical Trial Summary

About 300,000 people are hospitalized for traumatic brain injury (TBI) each year. After TBI, secondary brain injury escalates due in part to heightened levels of oxidant injury, inflammation, and vascular injury. Traumatic cerebral vascular injury (TCVI) may begin almost immediately after the primary injury and evolve into chronic neurodegenerative conditions. TCVI is a very complex TBI endophenotype and microvascular injuries have been described in a plethora of animal and human TBI studies. These injuries consist of endothelial injury, disruption of the blood brain barrier (BBB), a reduction of capillary density, intravascular microthrombi, and white-matter degeneration. Recently, use of magnetic resonance imaging (MRI)-Blood Oxygen Level Dependent (BOLD) combined with hypercapnia (high spatial and temporal resolution) by our research group has proven to be more sensitive at measuring alterations of cerebral blood flow (CBF) in TBI subjects. The goal of the proposed research is to test the efficacy of Viagra® (sildenafil) at normalizing CBF and improving cognitive outcomes in people that have experienced a TBI. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor that has previously been administered as a therapy for high blood pressure and erectile dysfunction. In people that have been affected by stroke-induce neurotrauma, sildenafil improved CBF and was found to be neuroprotective. With respect to chronic TBI, previous studies have demonstrated that sildenafil therapy potentiates cardiovascular reactivity (CVR) in areas of the brain with damaged endothelium. In this proposal, the investigators will test the hypothesis that sildenafil treatment in boxers/Mixed Martial Arts (MMA) fighters soon after concussion normalizes CBF, potentiates CVR, reduces post-concussion symptoms, and improves cognition.

Clinical Trial Description

In this study, 100 professional boxers that experience a concussion will be enrolled, randomized to either placebo or sildenafil (60mg) drug treatment, and arterial spin labeling and BOLD-MRI with hypercapnia will used to assess CBF and CVR, respectively. Symptom reporting, blood biomarkers, and neuropsychological testing will also be conducted. The timepoints for this study are baseline (pre-fight), and once between days 1 and 3 and day 30 after injury. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03598140
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact
Status	Terminated
Phase	Phase 2
Start date	July 25, 2018
Completion date	May 29, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04109677` - AIM CONTROL and SWECON - Handball The SWEdish CONcussion Study in Elite Handball
Recruiting	`NCT04932278` - The Role of Osteopathic Manipulative Medicine in Recovery From Concussions	N/A
Withdrawn	`NCT05062148` - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery	N/A
Recruiting	`NCT05682677` - Combined Neuromodulation and Cognitive Training for Post-mTBI Depression	N/A
Recruiting	`NCT04992130` - Sport Concussion Performance-Based Prevention Program	N/A
Completed	`NCT05095012` - RECOVER Clinical Pathway for Pediatric Concussion	N/A
Recruiting	`NCT05886400` - The Effects of Environmental Distractions on SCAT6 Outcomes	N/A
Active, not recruiting	`NCT05400551` - Craneofacial Injuries in Rink Hockey Athletes
Recruiting	`NCT04121780` - Growth Hormone Replacement Therapy for Retried Professional Football Players	Phase 2
Withdrawn	`NCT03575741` - Postural Control in Children and Adolescents After Suffering From a Concussion
Active, not recruiting	`NCT05471791` - Development of a Concussion Management Platform for Children and Youth	N/A
Completed	`NCT04730167` - The Monaco Initiative for Concussion in Motorsport Pilots
Completed	`NCT03478059` - Dual-task Assessment and Rehabilitation for Individuals With Residual Symptoms After mTBI	N/A
Recruiting	`NCT05685121` - A Wrist-Worn Nerve Stimulator for Remediating Persistent Post-Concussive Symptoms in Adolescents	N/A
Completed	`NCT04122274` - Comparing and Interactive Concussion Education Platform to Current Education Standards	N/A
Completed	`NCT04558346` - Ghrelin (OXE--103) for Acute Concussion Management	Phase 2
Completed	`NCT04074486` - Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
Not yet recruiting	`NCT05562232` - The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms	N/A
Recruiting	`NCT05326555` - Dynamic Vision Testing and Concussion Management Dream Team 65
Completed	`NCT03671083` - Validation of Brain Function Assessment Algorithm for mTBI/Concussion

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.